![Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting | Business Wire Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting | Business Wire](https://mms.businesswire.com/media/20220606005041/en/739014/23/teva_RGB_JPEG.jpg)
Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting | Business Wire
![Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, Join a Growing List of Provinces Providing Public Drug Plan Reimbursement for Teva Canada's AJOVY® (fremanezumab), for the Preventive Treatment of Migraine in Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, Join a Growing List of Provinces Providing Public Drug Plan Reimbursement for Teva Canada's AJOVY® (fremanezumab), for the Preventive Treatment of Migraine in](https://smartcdn.gprod.postmedia.digital/financialpost/wp-content/uploads/2022/05/bw20220512006052_ajovy_box_2825_29.jpeg)
Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, Join a Growing List of Provinces Providing Public Drug Plan Reimbursement for Teva Canada's AJOVY® (fremanezumab), for the Preventive Treatment of Migraine in
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AJOVY safely and effecti
Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting
![Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults | Business Wire Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults | Business Wire](https://mms.businesswire.com/media/20210408005437/en/868792/5/Teva_Canada_-_AJOVY_Autoinjector.jpg)
Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults | Business Wire
![No joy for Ajovy: Teva's migraine drug can't find a convincing win in meta-analysis versus Biohaven, AbbVie meds | Fierce Pharma No joy for Ajovy: Teva's migraine drug can't find a convincing win in meta-analysis versus Biohaven, AbbVie meds | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1631128798/AJOVY%20Image.jpg/AJOVY%20Image.jpg?VersionId=syVEFjOv7_Oy_I9QN1IbMNNg6mpwQsTc)